Category Archives: HSA

NMPA’s CMDE Opens Public Consultation on Revised Guidelines for Tuberculosis Drug‑Resistance Gene Mutation Detection Reagents – 2026 Revision Signals Tightened Review Standards for Molecular TB Diagnostics in China

Consultation Snapshot

Item	Detail
Agency	CMDE, under the National Medical Products Administration (NMPA), China
Action	Public solicitation of opinions on a revised draft registration review guideline
Document	Guidelines for Registration and Review of Mycobacterium tuberculosis Complex Resistance Gene Mutation Detection Reagents (2026 Revised Edition, Draft for Comments)
Purpose	Standardize technical review requirements; guide applicants in preparing and writing registration dossiers
Notice Date	16 September 2026
Comment Deadline	15 October 2026, via email using the prescribed feedback form and subject‑line naming convention
Original Notice	cmde.org.cn (published 16 September 2026)

Guideline Scope & Submission Channels

Product Scope: The guideline covers in vitro diagnostic reagents that detect resistance‑associated gene mutations in the Mycobacterium tuberculosis complex — molecular tests used to identify drug‑resistant TB (including multidrug‑resistant TB) directly from clinical specimens, in contrast to slower culture‑based drug susceptibility testing.
Revision, Not First Edition: CMDE has revised the existing guideline rather than issuing an inaugural document, indicating updates to review expectations accumulated from prior registration experience. The specific changes were not disclosed in the notice; the full draft is available for download from CMDE.
Submission Format: Comments must be filed via the official feedback form (Annex 2) by email, with subject lines and file names formatted as “Guideline name – feedback + organization name.”
Contacts: Cheng Xi, Liu Rongzhi (+86‑10‑86452580, +86‑10‑86452532; chengxi@cmde.org.cn, liurz@cmde.org.cn).

Sector Background

Molecular Resistance Detection: Gene mutation assays — typically PCR‑based — identify resistance‑conferring mutations (e.g., in rpoB for rifampicin resistance) within hours, enabling rapid treatment decisions versus weeks for phenotypic testing.
Public Health Priority: China remains among the countries with the highest TB and multidrug‑resistant TB burden globally, making fast, accurate resistance detection central to national TB control programs and the WHO End TB Strategy.
IVD Registration Environment: CMDE technical review guidelines define the evidentiary expectations (analytical performance, clinical studies, reference comparators) for IVD registration in China; public consultation is the standard step before finalization.

Market Impact & Outlook

Regulatory Predictability: A revised, codified standard reduces dossier ambiguity for IVD sponsors and shortens the review cycle for resistance‑detection assays targeting the M. tuberculosis complex.
Competitive Landscape: Domestic molecular diagnostics developers — alongside global IVD players active in China’s TB testing market — should benchmark their clinical evidence and performance claims against the 2026 draft before launching new registrations or renewals.
Portfolio Implications: Manufacturers with existing TB resistance‑detection products should assess whether current dossiers and performance data meet the revised expectations, particularly on mutation coverage and clinical concordance requirements.
Participation Window: Stakeholders have until 15 October 2026 to influence the final guideline — an opportunity to raise practical issues on reference standards, comparator selection, and multi‑center clinical study design.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding regulatory timelines, the finalization of the draft guideline, and its potential impact on in vitro diagnostic registration in China. The draft is subject to revision based on public feedback, and actual requirements, effective dates, and review outcomes may differ materially.-China Health Reform Pulse

Policy Source: https://www.cmde.org.cn/xwdt/zxyw/20260916144510144.html

NMPA’s CMDE Opens Public Consultation on Draft Review Guidelines for AI Multi‑Disease Decision Devices and Deep Brain Stimulation Systems – Standardized Review Pathways Signal Next Phase of China MedTech Regulation

Consultation Snapshot

Item	Detail
Agency	CMDE, under the National Medical Products Administration (NMPA), China
Action	Public solicitation of opinions on two draft technical review guidelines
Document 1	AI‑assisted multi‑disease decision‑making medical devices – clinical evaluation & registration review
Document 2	Implantable deep brain stimulation (DBS) systems – clinical evaluation & registration review
Notice Date	15 September 2026
Comment Deadline	14 October 2026, via email using the prescribed feedback form and subject‑line naming convention
Original Notice	cmde.org.cn (published 16 September 2026)

Guideline Scope & Submission Channels

Document 1 – AI Multi‑Disease Decision Devices: Targets software‑based devices that assist clinical decision‑making across multiple diseases, defining clinical evaluation and registration review requirements. Detailed technical provisions were not disclosed in the notice itself; the full draft is available for download from CMDE.
Document 2 – Implantable DBS Systems: Sets out clinical evaluation and registration review requirements for implantable deep brain stimulation systems, a class of active implantable neurostimulation devices.
Submission Format: Comments must be filed via the official feedback form (Annex 3) by email, with subject lines and file names formatted as “Guideline name – feedback + organization name.”
Contacts – AI Guideline: Wang Zehua, Jiang Yan, Dong Zheng (wangzh@cmde.org.cn, jiangyan@cmde.org.cn, dongzheng@cmde.org.cn).
Contacts – DBS Guideline: Cui Xinyue, Guo Jiaying, Jin Yaxi (cuixy@cmde.org.cn, guojy@ydcmdei.org.cn, jinyx@cmde.org.cn) — with a Shanghai contact number indicating involvement of CMDE’s Yangtze River Delta branch.

Sector Background

AI as a Medical Device (SaMD): China has progressively built a review framework for AI‑enabled diagnostic software. Extending dedicated guidance to multi‑disease decision support reflects the regulator’s response to algorithms that synthesize patient data across indications rather than addressing a single disease — a materially more complex clinical evaluation problem.
Deep Brain Stimulation: DBS is an established implantable therapy for movement disorders such as Parkinson’s disease, with China’s market served by both global manufacturers (Medtronic, Abbott, Boston Scientific) and domestic players (PINS Medical, SceneRay).
Guideline System: CMDE technical review guidelines standardize registration dossiers and evaluation criteria; public consultation is the customary step before guidelines are finalized and take effect.

Market Impact & Outlook

Regulatory Clarity: Codified evaluation criteria for AI decision‑support software and implantable neurostimulators reduce approval uncertainty for developers and shorten pre‑submission negotiations.
AI‑MedTech Landscape: Sponsors of multi‑disease AI platforms — including hospital‑affiliated developers and health‑AI startups — should benchmark their clinical evidence strategies against the draft before the final guideline lands.
Neuromodulation Standardization: A dedicated DBS guideline aligns China’s review expectations with the maturity of its neurostimulation market, benefiting both multinationals and domestic manufacturers pursuing registration or next‑generation product iterations.
Participation Window: Industry stakeholders have until 14 October 2026 to shape the final requirements — an opportunity to flag practical concerns on clinical evaluation design, real‑world evidence, and post‑market obligations.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding regulatory timelines, the finalization of draft guidelines, and their potential impact on medical device registration in China. The drafts are subject to revision based on public feedback, and actual requirements, effective dates, and review outcomes may differ materially.-China Health Reform Pulse

Policy Source: https://www.cmde.org.cn/xwdt/zxyw/20260916105408164.html

NMPA and SAMR Discipline Body Hold Half‑Year Governance Meeting – Innovation Support for Drugs and Medical Devices Takes Center Stage

Meeting Snapshot

Item	Detail
Date	15 September 2026
Convening Bodies	NMPA Party Group; Discipline Inspection and Supervision Group stationed at SAMR (CCDI/NSC)
Format	Regular half‑year consultation meeting on comprehensive strict Party governance
Core Agenda	Political oversight plus dedicated consultation on supporting innovative drugs and medical devices
Key Attendees	Lin Guoyao (SAMR supervision group head); Huang Guo (NMPA Party Group Secretary & Administrator); NMPA Party Group members Lei Ping, Yang Sheng, Wang Weidong; heads of relevant NMPA departments and directly affiliated units
Stated Results	Progress report on H1 2026 consultation tasks; deployment of supervisory recommendations for H2

Supervisory Assessment – Lin Guoyao

Reform Track Record: The NMPA has deepened review and approval reform under the “Four Strictest” requirements — strictest standards, supervision, punishment, and accountability — driving year‑on‑year growth in approvals of innovative drugs and devices, described as an “acceleration” in promoting innovation, while acknowledging remaining shortcomings.
Execution Discipline: Strengthen organizational leadership and reform‑advancement mechanisms, with enhanced inspection, tracking, and accountability to implement reform tasks in detail.
Development–Safety Balance: Proactively empower innovative drug and device R&D while comprehensively upgrading drug safety regulatory capacity to detect and处置 risks early.
“Three‑Medical” Coordination: More actively integrate into the coordinated development and governance of healthcare, medical insurance, and pharmaceuticals, align regulation with clinical needs, and guide local coordination of reform measures.
Global Engagement: Deepen international regulatory cooperation and mutual recognition, assess industry trends precisely, and integrate further into global drug and device safety governance.
Regulatory Science & Talent: Promote deep integration of regulatory science with industrial development and implement the guidance on strengthening drug regulation talent work in the new era.

NMPA Deployment – Huang Guo

H1 Review: Reported progress on H1 2026 consultation tasks and the NMPA’s work supporting innovative development across drugs, medical devices, and cosmetics; deployed implementation of the supervision group’s recommendations.
“Service + Review & Approval” Mechanism: Refine the new service‑oriented approval mechanism to encourage pharmaceutical R&D innovation, advance cell and gene therapy drug development and new‑method research, and support high‑level self‑reliance in medical devices.
Lifecycle Regulation: Strengthen full‑lifecycle oversight — institutionalize drug safety risk consultation, intensify quality supervision of centrally procured (VBP) winning products, and enhance post‑market monitoring and evaluation of innovative products.
Modernization & AI: Advance modernization of drug regulation, deepen the application of artificial intelligence in regulatory work, intensify regulatory science research, and participate deeply in global drug safety governance.
Strict Governance: Compact political responsibility for Party administration, maintain a high‑pressure anti‑corruption posture, continue the “Qinglang Yaojian” (Clear and Bright Drug Regulation) special campaign, and improve constraints and supervision over the exercise of power.

Industry Impact & Outlook

Approval Momentum: The leadership’s framing — rising innovative drug and device approval counts attributed to sustained review‑reform “acceleration” — signals continuity of the pro‑innovation approval posture into H2 2026 and beyond.
Frontier Modalities: Explicit backing for cell and gene therapy development and device self‑reliance points to sustained policy support for advanced‑therapy sponsors and domestic device manufacturers.
VBP Quality Scrutiny: Heightened supervision of centrally procured winning products raises the compliance bar for manufacturers holding volume‑based procurement awards — quality performance will be watched as closely as price.
AI‑Enabled Regulation: Deepening AI application in regulatory work suggests evolving review workflows and data expectations for industry submissions.
Governance Overlay: The coupling of Party‑governance discipline with regulatory policy underscores that reform execution and anti‑corruption compliance remain central to the NMPA’s operating model.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding NMPA regulatory reform priorities, supervision of innovative drugs and medical devices, and governance initiatives for the second half of 2026. Actual implementation may differ based on policy decisions, supervisory review outcomes, and evolving regulatory practice.-China Health Reform Pulse

Policy Source: https://www.cmde.org.cn/xwdt/zxyw/20260916083706136.html